OptiNose, Inc. (NASDAQ:OPTN) Q4 2023 Earnings Call Transcript

Having said that, we also think it’s very important that a much broader range of physicians, including those who are not able to do nasal endoscopy in office, will be able to and comfortable in making the diagnosis of chronic sinusitis a much broader range and with more frequency than we’re comfortable making the diagnosis of nasal polyps.

David Amsellem: Okay. That’s helpful. Thank you.

Operator: Thank you. [Operator Instructions] And this completes our Q&A portion. I’ll turn the call back to Dr. Ramy Mahmoud for closing remarks.

Ramy Mahmoud: I’d like to thank you all for joining us this morning. We’re very pleased with the results of 2023, but even more so, we’re excited about the prospects for 2024. We’re looking forward to hearing from FDA on their target action date. And should that be an approval, we’re looking forward to an assertive launch of the product into the marketplace starting in second quarter. We believe there’s a large number of patients whose suffering can be alleviated by this product, and we think that can be a solid base for growing the company both in the chronic sinusitis space and looking further forward into the future with other ENT and allergy products that are synergistic with the product we’re selling today. So again, thank you for joining this morning.

Operator: This concludes today’s conference call. Thank you for your participation. You may now disconnect. Everyone, have a wonderful day.